0.00Open1.35Pre Close0 Volume10 Open Interest2.00Strike Price0.00Turnover308.10%IV38.10%PremiumOct 18, 2024Expiry Date0.95Intrinsic Value100Multiplier14DDays to Expiry0.40Extrinsic Value100Contract SizeAmericanOptions Type-0.7850Delta0.4711Gamma1.05Leverage Ratio-0.0062Theta-0.0006Rho-0.82Eff Leverage0.0006Vega
Cue Biopharma Stock Discussion
Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting
Cue Biopharma (Nasdaq: CUE) announced two presentations at the Society for Immunotherapy of Cancer's 39th Annual Meeting (SITC 2024) in Houston, Texas, from November 6-10, 2024. The presentations will focus on their clinical assets CUE-101 and CUE-102, part of the CUE-100 series.
An oral presentation by Dr. Christine Chung will discuss a ph...
Cue Biopharma Presents Updated Data from Phase 1 Trial of CUE-101 in Recurrent/Metastatic HPV+ Head and Neck Cancer at the 2024 ASCO Annual Meeting
Cue Biopharma has presented updated data from its Phase 1 trial of CUE-101 at the 2024 ASCO Annual Meeting, revealing promising results for HPV+ head and neck cancer. The combination of CUE-101 and pembrolizumab in first-line (1L) treatment showed a 46% overall response rate (ORR) and a 96% 12-month overall survival (OS). ...
NEED IT TO BREAK OVER: $15.40
key indicator for MORE uptrend $15.55
confirmation uptrend - $16.16
mini breakout - $16.37
full breakout - $17.31
SEMI PARABOLIC - $18.25
stop loss - $14.31
support - $12.98. $Cue Biopharma (CUE.US)$
No comment yet